Anavex Life Sciences Corp (AVXL)

[rx7171]

It is irritating that if true that the EMA after reviewing data in hand from the 2b/3 trial strongly encouraged an application, knowing the size of the trial, the dropout rates, its safety profile and meeting one of its primary targets and secondary ones and now feeling the data no longer is sufficient and sandbagging the company after a year of looking at the data and asking supplementary questions.